Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Stopped early · Phase 1

Conditions studied: Lung Cancer, Soft Tissue Sarcoma, Colorectal Carcinoma, Breast Cancer, Prostate Cancer

In brief

To determine the molecular interaction in tumor samples between docetaxel and lonafarnib.

Key facts

Study ID

NCT00288444

Run by

Emory University

People needed

38

Starts

2006-01-01

Expected to finish

2009-03-01

Last updated by the study team

2012-12-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• 2.1 Patient has received more than three previous chemotherapy regimens.
• 2.2 Patient is pregnant or breast feeding.
• 2.3 Patient has signs of symptoms of acute infection requiring systemic therapy.
• 2.4 Patient exhibits confusion, disorientation, or has a history of major psychiatric illness which may impair the patient's understanding of the informed consent.
• 2.5 Patient's life expectancy is less than 12 weeks.
• 2.6 Patient has > Grade 1 neurotoxicity from previous anticancer treatment or significant neuropathy from any cause.
• 2.7 Patient requires total parenteral nutrition with lipids.
• 2.8 Inability to swallow the lonafarnib BID.
• 2.9 Patient has a history of uncontrolled heart disease (including clinically significant coronary artery disease, congestive heart failure and symptomatic or uncontrolled arrythmias).
• 2.10 Patient has a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. Symptoms include: any reaction such as bronchospasm, generalized urticaria, systolic BP ≤ 80mm Hg, and angioedema.
• 2.11 Use of chronic steroids or anticonvulsants.

Where it is running

• Emory University Winship Cancer Institute — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.